Related references
Note: Only part of the references are listed.Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73-and E2F1-mediated expression of PUMA and Siva-1
Ramesh M. Ray et al.
APOPTOSIS (2011)
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Jane M. Valentine et al.
BMC CANCER (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
Tom Van Maerken et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
M. H. Aziz et al.
ONCOGENE (2011)
Reactivation of p53: from peptides to small molecules
Christopher J. Brown et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
DNA damage response to the Mdm2 inhibitor Nutlin-3
Rajeev Verma et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines
Martin Michaelis et al.
BIOCHEMICAL PHARMACOLOGY (2010)
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Jane Carr-Wilkinson et al.
CLINICAL CANCER RESEARCH (2010)
Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells
Florian Rothweiler et al.
NEOPLASIA (2010)
MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
J. A. Canner et al.
BRITISH JOURNAL OF CANCER (2009)
Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
Martin Michaelis et al.
CANCER RESEARCH (2009)
Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells
Mitsuru Miyachi et al.
CLINICAL CANCER RESEARCH (2009)
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Lee M. Ellis et al.
CLINICAL CANCER RESEARCH (2009)
Selective Enrichment of Hepatocellular Cancer Stem Cells by Chemotherapy
S. Tan et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2009)
Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
Tom Van Maerken et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Transient Nutlin-3a Treatment Promotes Endoreduplication and the Generation of Therapy-Resistant Tetraploid Cells
Hong Shen et al.
CANCER RESEARCH (2008)
A multicolor panel of novel lentiviral gene ontology (LeGO) vectors for functional gene analysis
Kristoffer Weber et al.
MOLECULAR THERAPY (2008)
The role of p53 in pigmentation, tanning and melanoma
Neil F. Box et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Drug-Selected Human Lung Cancer Stem Cells: Cytokine Network, Tumorigenic and Metastatic Properties
Vera Levina et al.
PLOS ONE (2008)
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1
G. Ambrosini et al.
ONCOGENE (2007)
The oncogenic roles of p53 mutants in mouse models
Guillermina Lozano
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways
Huaiyu Mi et al.
NUCLEIC ACIDS RESEARCH (2007)
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells
Keiran S. M. Smalley et al.
CANCER RESEARCH (2007)
MDM2 inhibitors for cancer therapy
Lyubomir T. Vassilev
TRENDS IN MOLECULAR MEDICINE (2007)
Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse
J Carr et al.
CANCER RESEARCH (2006)
West Nile virus infection induces interferon signalling in human retinal pigment epithelial cells
J Cinatl et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
Spectrum of p53 tumor suppressor gene mutations and breast cancer survival
H Lai et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
The p53 pathway and its inactivation in neuroblastoma
DA Tweddle et al.
CANCER LETTERS (2003)
Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model
R Kotchetkov et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Transcription, genomes, function
RJ Cho et al.
TRENDS IN GENETICS (2000)
Share Paper
